Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.96 |
| ▸ | NPY1R | P25929 | 1/20 | 0.96 |
| ▸ | NPY2R | P49146 | 1/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.80 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL41104 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL29995613 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL1649321 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL4881939 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL29367290 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL19211129 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| (S)-Metoprolol SCHEMBL141366 | 0.98 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL2124595 | 0.97 | TDP1 (0.98) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL28264735 | 0.94 | TDP1 (0.94) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL6049972 | 0.92 | ADRB1 (0.95) | TDP1PMP22NPY1RNPY2RNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161372-A1 | Methods for the Treatment of Hypertension | MERCK & CO., INC. | 2008-07-03 | — | — | US | disclosed |
| US-20070191438-A1 | Methods for the treatment of hypertension | ROHRER SUSAN P | 2007-08-16 | — | — | US | disclosed |
| EP-1734958-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1734960-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005099700-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005099704-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191438-A1 | Methods for the treatment of hypertension | EDNRA, GPER1, EDNRB | ADRB1 29/4885TDP1 3262/4885PMP22 2862/4885 |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | EDNRA, GPER1, EDNRB | ADRB1 29/4885TDP1 3262/4885PMP22 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.